

Background and Brief Description

CDC is requesting OMB approval to revise information collection for the Behavioral Risk Factor Surveillance System (BRFSS). The BRFSS is a nationwide system of annual, cross-sectional telephone health surveys sponsored by CDC. BRFSS coordinators in health departments in U.S. states, territories, and the District of Columbia (collectively referred to as states) collaborate with CDC on questionnaire content and survey administration.

An independent sample of adult, non-institutionalized respondents is drawn each for each state and is based on the state's parameters for state-level or sub-state analysis. Each state's annual questionnaire is based on a common core that is administered by all states. In addition, CDC provides support for standardized optional modules that states can use to collect customized content. Information collection is conducted in a continuous, three-part telephone interview process: Screening, participation in core BRFSS questions,

and participation in the optional question modules. Both the core survey and the optional modules are updated annually.

CDC requests OMB approval to incorporate a limited annual field test into the BRFSS clearance. Field testing will be conducted approximately 5–8 months in advance of the principal BRFSS survey. Field tests are used to identify problems with new or updated questions, instrument documentation or instructions, software errors, or other implementation issues. Field tests are typically conducted in one state. Addition of the annual field test will increase the estimated annualized number of responses by 900 and the estimated annualized burden by 382 hours. These estimates include allocations for both respondent screening and completion of the field test survey. Each year CDC will use the Change Request mechanism to request OMB approval of the annual Field Test Supplement.

CDC and the states will continue to use BRFSS data to produce state-level

information about adults 18 years and older. BRFSS topics include health risk behaviors, health conditions, and preventive health practices that are associated with chronic diseases, infectious diseases, and injury. This information is used by state and local health departments to plan and evaluate public health programs at the state or sub-state level. In addition, CDC makes annual BRFSS data sets available for public use and provides guidance on statistically appropriate uses of the data.

Field test results will not be incorporated into the analytic data sets. Field test results are used exclusively to inform the development of the upcoming year's BRFSS questionnaire and the technical assistance that CDC provides to states.

OMB approval is requested for three years. Participation in the BRFSS is voluntary and there are no costs to respondents other than their time. The total estimated annualized burden hours are 256,297.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hr)
U.S. General Population	Landline Screener	440,486	1	1/60
	Cell Phone Screener	223,334	1	1/60
Adults ≥18 Years	Field Test Screener	400	1	1/60
	Core Survey	494,650	1	15/60
	Optional Modules	484,757	1	15/60
	Field Test Survey	500	1	45/60

Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2016–09189 Filed 4–20–16; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2016–N–0832]

Phibro Animal Health Corp.; Carbadox in Medicated Swine Feed; Opportunity for Hearing; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of opportunity for hearing; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a

notice that appeared in the **Federal Register** on April 12, 2016 (81 FR 21559). The document announced an opportunity for a hearing on FDA's Center for Veterinary Medicine's proposal to withdraw approval of all new animal drug applications providing for use of carbadox in medicated swine feed and contained an incorrect telephone number for the individual to be contacted for further information. The address for Phibro Animal Health Corp. was also incorrect. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Vernon Toelle, Center for Veterinary Medicine (HFV–234), 7519 Standish Pl., Rockville, MD 20855, 240–402–7001.

SUPPLEMENTARY INFORMATION: In FR Doc. 2016–08327, appearing on page 21559 in the **Federal Register** of Tuesday, April 12, 2016, the following corrections are made:

1. On page 21560, in the second column, in the **FOR FURTHER**

INFORMATION CONTACT paragraph, the telephone number is corrected to read “240–402–7001”.

2. On page 21560, in the third column, in the first paragraph, the address for Phibro Animal Health Corp. is corrected to read “GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ 07666”.

3. On page 21572, in the first column, in the third paragraph, the address for Phibro Animal Health Corp. is corrected to read “GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ 07666”.

Dated: April 18, 2016.

Tracey Forfa,
Acting Director, Center for Veterinary Medicine.

[FR Doc. 2016–09265 Filed 4–20–16; 8:45 am]

BILLING CODE 4164–01–P